肾移植后使用双膦酸盐与骨折风险降低相关
该回顾性研究纳入2000至2019年南加州Kaiser Permanente肾移植合并骨质疏松患者489例,其中203例使用口服双膦酸盐。病因特异性风险模型显示双膦酸盐组非椎体骨折风险降低64%(P=0.02),但Fine-Gray竞争风险模型未显示相对发生率降低。双膦酸盐使用还与死亡删失的移植物失败率降低相关(P=0.002)。
要点
- 肾移植后使用双膦酸盐与病因特异性非椎体骨折风险降低64%相关(P=0.02)。
- 将死亡作为竞争风险后,双膦酸盐与非椎体骨折相对发生率降低无显著关联。
- 双膦酸盐使用与死亡删失的移植物失败率降低相关(P=0.002)。
核心结论
- 肾移植后使用双膦酸盐可能与移植后非椎体骨折风险降低相关。
- 双膦酸盐使用还与死亡删失的移植物失败率降低相关。
- 鉴于研究的回顾性性质,解释结果时需谨慎。
研究设计与样本
- 回顾性综述南加州Kaiser Permanente 2000至2019年肾移植合并骨质疏松患者。
- 共纳入489例患者,其中203例使用口服双膦酸盐,与未使用者比较。
- 主要结局为非椎体骨折,采用倾向评分平衡协变量,并行竞争风险分析。
主要发现
- 病因特异性风险模型显示双膦酸盐组非椎体骨折风险降低64%(P=0.02)。
- Fine-Gray模型将死亡作为竞争风险,未显示非椎体骨折相对发生率降低。
- 双膦酸盐治疗与死亡删失的移植物失败率降低相关(P=0.002)。
临床怎么用
- 对肾移植合并骨质疏松患者,可考虑使用双膦酸盐以可能降低非椎体骨折风险。
- 双膦酸盐使用可能还与降低死亡删失的移植物失败相关。
- 需结合竞争风险(如死亡)综合评估双膦酸盐的骨折预防效果。
局限性
- 研究为回顾性设计,结果解释需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Bisphosponate use may decrease the risk of fracture in patients receiving kidney transplant. Identifying those at risk of fracture after kidney transplant is critical. BACKGROUND: Kidney transplant recipients are at higher risk of fractures compared with the general population. The use of bisphosphonates has been shown to increase bone mineral density after transplantation but has not been shown to lower fracture rates. In this study, we aim to determine whether exposure to bisphosphonates is associated with lower incidence of nonvertebral fractures after kidney transplantation. METHODS: We conducted a retrospective review for all Southern California Kaiser Permanente kidney transplant recipients with osteoporosis transplanted between 2000 and 2019. Baseline variables were collected. Those prescribed an oral bisphosphonate were compared with those who were not. The primary outcome was nonvertebral fracture. Chi-square test was used to evaluate categorical variables and Wilcoxon rank-sum test for continuous variables. Propensity scores were generated to balance covariates in the bisphosphonate and nonbisphosphonate groups. Cause-specific hazard and subdistribution (Fine-Gray) methods were performed for competing risk analysis. Death-censored graft survival was evaluated as a secondary outcome using standard Cox regression. RESULTS: There were 489 patients included in the study, 203 of which were in the bisphosphonate group. The cause-specific hazard model suggested a 64% lower risk of nonvertebral fracture in the bisphosphonate group ( P = 0.02). The Fine-Gray hazard model treating death as a competing risk did not show lower relative incidence of nonvertebral fracture. Bisphosphonate treatment was associated with lower death-censored graft failure ( P = 0.002). CONCLUSIONS: Bisphosphonate use after kidney transplantation may be associated with a lower risk of nonvertebral fracture after transplant. Bisphosphonate use in this study was also associated with lower death-censored graft failure. Caution is advised when interpreting these results given the retrospective nature of the study.
引用
- Kahwaji JM, Yang SJ, Sim JJ, et al. Bisphosphonate Use after Kidney Transplantation Is Associated with Lower Fracture Risk. Clin J Am Soc Nephrol. 2024. PMID: 39499576. doi:10.2215/CJN.0000000591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。